COMPANY

Fore Biotherapeutics

HQ: Philadelphia, PA source · fore.bio ↗

Keywords: oncology cancer Lung Cancer Cancer Harboring BRAF Alterations BRAF-mutated Tumors Melanoma Thyroid Cancer Colorectal Cancer Non-small Cell Lung Cancer Cholangiocarcinoma Histiocytosis Hairy Cell Leukemia Plixorafenib FORE8394 PLX8394

Location: Philadelphia, PA · source · Oct 12, 2026

Profile checked Oct 10, 2026

$105.4MRaised (2 yrs)7Trials (company is sponsor)

Raises and deals from press releases

Raise Series D · $67.4M · announced Jul 7, 2026 Company release ↗
Source quote
- Jul 7, 2026 · Company release ↗
  “FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements”

Raises announced in these releases: $67.4M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jul 7, 2026 Raise Private equity round — Series D-2 Extension: $67.4M (total, as published), announced Jul 7, 2026. Source: company's own press page. source ↗
Jul 7, 2026 Raise Series D · $67.4M source ↗
May 22, 2025 Raise Private equity round — Series D-2: $38M (total, as published), announced May 22, 2025. Source: company's own press page. source ↗
Apr 24, 2024 Trial start Phase 1: A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants. source ↗
Feb 21, 2023 Trial start Phase 2: A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations source ↗
2015-04 Trial start Phase 1/Phase 2: A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors source ↗
2014-10 Trial start —: NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients source ↗
2014-02 Trial start I: Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. source ↗
2014-01 Trial start —: NovellusDx Tissue Collection Protocol source ↗
2013-06 Trial start —: NovellusDx Cancer Early Detection Blood Test- Clinical Trial source ↗

Upcoming milestones

Dec 31, 2027 (ESTIMATED) · Phase 2 · A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations · NCT05503797

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $105.4M. Last 2 years.

Jul 7, 2026 Private equity round — Series D-2 Extension: $67.4M (total, as published), announced Jul 7, 2026. Source: company's own press page. source ↗
May 22, 2025 Private equity round — Series D-2: $38M (total, as published), announced May 22, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT05503797	A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations	Phase 2	Recruiting	Feb 21, 2023	Dec 31, 2027 (estimated)
NCT06385119	A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.	Phase 1	Completed	Apr 24, 2024	Dec 22, 2024 (actual)
NCT02428712	A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors	Phase 1/Phase 2	Completed	2015-04	Jul 12, 2024 (actual)
NCT02012231	Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.	I	Terminated	2014-02	2014-09 (actual)
NCT02274025	NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients	Not listed	Completed	2014-10	2016-10 (actual)
NCT01883388	NovellusDx Cancer Early Detection Blood Test- Clinical Trial	Not listed	Completed	2013-06	2016-12 (actual)
NCT01791322	NovellusDx Tissue Collection Protocol	Not listed	Completed	2014-01	2016-06 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗